Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/S1677-54492011000400006
Jornal Vascular Brasileiro
Original Article

Levels of apolipoproteins as risk factors for coronary artery disease

Níveis de apolipoproteínas como fatores de risco para doença arterial coronariana

Mohmed Ashmaig; Khalifa Ashmeik; Atif Ahmed; Samia Sobki; Muheeb Abdulla

Downloads: 0
Views: 86

Abstract

INTRODUCTION: The Saudi population is renowned for their unhealthy diet and physical inactivity. OBJECTIVE:To investigate apolipoproteins B (apo B), A-I (apo A-I) and B/A-I as risk factors that might be associated with increased incidence of the coronary artery disease. METHODS: Two hundred and twenty subjects suspected of having the coronary artery disease underwent coronary angiography and blood draw following a 12-hour fast. Apolipoproteins B and A-I were both measured by turbidimetric methods. RESULTS: One hundred and forty subjects were positive and 80 subjects were negative for the coronary artery disease. Both apolipoproteins were found to be statistically significant as risk factors for the coronary artery disease: apolipoprotein B (105.33±29.22 versus 94.56±24.35 mg/dL, p<0.003), apolipoprotein A-I (123.98±25.6 versus 133.5±24.1 mg/dL, p<0.004) and apolipoproteins B/A-I (0.88±0.28 versus 0.72±0.2, p<0.0001). CONCLUSIONS:Measurements of apolipoproteins B, A-I and calculation of apolipoproteins B/A-I ratio either instead of or in addition to the customary measurements of lipoprotein cholesterol may significantly add to predicting and assessing the coronary risk factors in the Saudi population.

Keywords

apolipoprotein B, apolipoprotein A-I, coronary artery disease

Resumo

INTRODUÇÃO: A população da Arábia Saudita é conhecida por sua dieta não-saudável e inatividade física. OBJETIVO: Investigar as apolipoproteínas B (apo B), AI (apo AI) e B/AI como fatores de risco que podem estar associados ao aumento da incidência da doença arterial coronariana. MÉTODOS: Duzentos e vinte pacientes com suspeita de doença art RESULTADOS: Cenerial coronariana foram submetidos à angiografia coronária e extração de sangue após jejum de 12 horas. As apolipoproteínas B e AI foram medidas por métodos turbidímetros.to e quarenta pacientes foram positivos e 80 foram negativos para a doença arterial coronariana. Ambas apolipoproteínas foram estatisticamente significativas como fatores de risco para doença arterial coronariana: apolipoproteínas B (105,33±29,22 versus 94,56±24,35 mg/dL, p<0,003), AI (123,98±25,6 versus 133,5±24,1, p<0,004) e B/A-I (0,88±0,28 versus 0,72±0,2, p<0,0001). CONCLUSÕES: As medidas das apolipoproteínas B, AI e o cálculo da relação B/AI tanto por ou em adição às medidas habituais de colesterol das lipoproteínas podem aumentar significativamente a previsão e avaliação dos fatores de risco coronariano na população saudita.

Palavras-chave

apolipoproteína B, apolipoproteína A-I, doença da artéria coronariana

References

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.

Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipidmodifying therapy. J Intern Med.. 2004;255:188-205.

Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J.. 2005;26:210-2.

Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med.. 2006;259:481-92.

Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Junger I. Apoproteins versus lipids as indices of coronary risk and as targets for statin therapy. Lancet. 2003;361:777-80.

Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108(19):2312-6.

Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol.. 1992;19(4):792-802.

Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol.. 2002;22:1918-23.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026-33.

Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation. 1996;94(3):273-8.

Sacks FM. The apolipoprotein story. Atheroscler Suppl.. 2006;7:23-7.

Warnick GR, Nguyen T, Albers AA. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem.. 1985;31:217-22.

Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipidlowering therapy--a review of the evidence. J Intern Med.. 2006;259:493-519.

Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med.. 2006;44:1015-21.

Khadem-Ansari M H, Rasmi Y, Rahimi-Pour A, Jafarzadeh M. The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease. Singapore Med J.. 2009;50(6):610-3.

Bolibar I, Thompson SG, von Eckardstein A, Sandkamp M, Assmann G. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis: Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group. Arterioscler Thromb Vasc Biol.. 1995;15:1035-42.

Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA.. 1996;276(11):875-81.

Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA.. 1996;276(11):882-8.

Krauss RM. Is the size of low-density lipoprotein particles related to the risk of coronary heart disease?. JAMA.. 2002;287(6):712-3.

Williams PT, Superko HR, Haskell WL, Alderman EL, Blanche PJ, Holl LG. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol.. 2003;23(2):314-21.

Mueller O, Chang E, Deng D, Franz T, Jing D, Kincaid R. PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med.. 2008;46(4):490-8.

5dde80cb0e8825467a7b23c6 jvb Articles
Links & Downloads

J Vasc Bras

Share this page
Page Sections